{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T04:18:03Z","timestamp":1791433083578,"version":"4.3.3"},"reference-count":50,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T00:00:00Z","timestamp":1713225600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000923","name":"Australian Research Council","doi-asserted-by":"publisher","award":["CE200100025"],"award-info":[{"award-number":["CE200100025"]}],"id":[{"id":"10.13039\/501100000923","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Aust N Z J Psychiatry"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>The Australian government recently rescheduled psilocybin and 3,4-methylenedioxymethamphetamine for limited clinical uses. This change has raised various regulatory concerns and challenges for the field of psychedelic-assisted therapy. To provide clarity, we aimed to comprehensively catalogue the matters relating to psychedelic-assisted therapy that are or could be regulated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We conducted a desktop review of the literature and current regulatory sources, semi-structured interviews with professionals who had expertise in fields relating to psychedelic-assisted therapy and a framework analysis to generate a taxonomy of relevant regulatory matters. In relation to each matter, we further identified what type of regulation (if any) currently applies to that matter, any uncertainty as to how the matter should be addressed in clinical practice in the context of current regulation and whether there are conflicting views as to how the matter could or should be further regulated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The taxonomy is structured into six main regulatory domains, three of which have a substantial proportion of matters with uncertainty or conflicting views: Service Establishment, Practitioner, and Treatment Delivery. Key examples of such matters include the location of services and facilities required, which professionals are eligible to become psychedelic therapists, and with what qualifications and experience. Matters in the remaining three domains, Patient Evaluation, Drug Supply and Service Oversight, appear by comparison relatively settled, with regulation either well-established or thought unnecessary.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The taxonomy provides a roadmap for health services establishing and implementing a psychedelic-assisted therapy program, or for government and other policymakers when determining areas that may require further regulation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/00048674241240597","type":"journal-article","created":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T02:47:53Z","timestamp":1713322073000},"page":"571-590","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":14,"title":["A taxonomy of regulatory and policy matters relevant to psychedelic-assisted therapy in Australia"],"prefix":"10.1177","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-4934-9042","authenticated-orcid":false,"given":"Samuel P","family":"Hatfield","sequence":"first","affiliation":[{"name":"Psychological Medicine, Central Clinical School, The University of Sydney, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5939-1339","authenticated-orcid":false,"given":"Nicollette LR","family":"Thornton","sequence":"additional","affiliation":[{"name":"Psychological Medicine, Central Clinical School, The University of Sydney, Sydney, NSW, Australia"},{"name":"Australian Research Council\u2019s Centre of Excellence for Children and Families over the Life Course, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0616-2070","authenticated-orcid":false,"given":"Kayla","family":"Greenstien","sequence":"additional","affiliation":[{"name":"Australian Research Council\u2019s Centre of Excellence for Children and Families over the Life Course, Sydney, NSW, Australia"},{"name":"School of Psychology, Faculty of Science, The University of Sydney, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0476-9146","authenticated-orcid":false,"given":"Nick","family":"Glozier","sequence":"additional","affiliation":[{"name":"Psychological Medicine, Central Clinical School, The University of Sydney, Sydney, NSW, Australia"},{"name":"Australian Research Council\u2019s Centre of Excellence for Children and Families over the Life Course, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,4,16]]},"reference":[{"key":"bibr1-00048674241240597","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2023.0549"},{"key":"bibr2-00048674241240597","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(20)30146-2"},{"key":"bibr3-00048674241240597","doi-asserted-by":"publisher","DOI":"10.1111\/soc4.12959"},{"key":"bibr4-00048674241240597","unstructured":"Australian Multidisciplinary Association for Psychedelic Practitioners (2023a) Accreditation guidelines. Available at: www.amapp.org\/accreditation-guidelines.html (accessed 4 April 2024)."},{"key":"bibr5-00048674241240597","unstructured":"Australian Multidisciplinary Association for Psychedelic Practitioners (2023b) Supervision Guidelines. Available at: https:\/\/amapp.org\/supervision-guidelines.html (accessed 4 April 2024)."},{"key":"bibr6-00048674241240597","unstructured":"Australasian Performing Right Association and Australasian Mechanical Copyright Owners Society (n.d.) Why do I need a licence? Available at: www.apraamcos.com.au\/music-licences\/music-licensing-explained\/why-do-i-need-a-licence (accessed 7 September 2023)."},{"key":"bibr7-00048674241240597","unstructured":"Australian Psychological Society (2023) Position statement: Psychologists and psychedelic-assisted therapy. Australian Psychological Society. Available at: https:\/\/psychology.org.au\/about-us\/position-statements\/psychologists-and-psychedelic-assisted-therapy (accessed 7 September 2023)."},{"key":"bibr8-00048674241240597","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.20220525"},{"key":"bibr9-00048674241240597","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2022.109214"},{"key":"bibr10-00048674241240597","doi-asserted-by":"publisher","DOI":"10.1177\/10398562231156684"},{"key":"bibr11-00048674241240597","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2022.887255"},{"key":"bibr12-00048674241240597","unstructured":"Chrysanthos N (2023) \u2018It\u2019s going to be for people with money\u2019: Psychedelic treatments tipped to cost at least $25,000. Available at: www.smh.com.au\/politics\/federal\/it-s-going-to-be-for-people-with-money-psychedelic-treatments-tipped-to-cost-at-least-25-000-at-first-20230313-p5crpd.html (accessed 5 February 2024)."},{"key":"bibr13-00048674241240597","doi-asserted-by":"publisher","DOI":"10.1177\/13634615221131465"},{"key":"bibr14-00048674241240597","doi-asserted-by":"publisher","DOI":"10.1017\/S0963180123000099"},{"key":"bibr15-00048674241240597","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0293349"},{"key":"bibr16-00048674241240597","unstructured":"Food and Drug Administration, US Department of Health and Human Services (2023) Psychedelic drugs: Considerations for clinical investigations, guidance for industry (draft guidance). Center for Drug Evaluation and Research, Food and Drug Administration, US Department of Health and Human Services. Available at: www.fda.gov\/media\/169694\/download (accessed 7 September 2023)."},{"key":"bibr17-00048674241240597","first-page":"2061","volume":"26","author":"Goldsmith LJ","year":"2021","journal-title":"Qualitative Report"},{"key":"bibr18-00048674241240597","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.20220528"},{"key":"bibr19-00048674241240597","volume":"44","author":"Hurst K","year":"2022","journal-title":"InPsych"},{"key":"bibr20-00048674241240597","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.800072"},{"key":"bibr21-00048674241240597","doi-asserted-by":"publisher","DOI":"10.1177\/02698811221133461"},{"key":"bibr22-00048674241240597","doi-asserted-by":"publisher","DOI":"10.1177\/00048674231174171"},{"key":"bibr23-00048674241240597","unstructured":"Kisely S, Connor M, Somogyi A (2021) An evaluation of the therapeutic value, benefits and risks of methylenedioxymethamphetamine (MDMA) and psilocybin for the treatment of mental, behavioural or developmental disorders: A report to the Therapeutic Goods Administration. Therapeutic Goods Administration, Commonwealth Government of Australia, 15 December. Available at: www.tga.gov.au\/resources\/publication\/publications\/independent-expert-panel-mdma-and-psilocybin (accessed 7 September 2023)."},{"key":"bibr24-00048674241240597","doi-asserted-by":"publisher","DOI":"10.17061\/phrp3332321"},{"key":"bibr25-00048674241240597","unstructured":"Lomax E (2017) Beyond the aetiology debate: The \u2018great LSD scandal\u2019 at Newhaven Private Hospital & the social foundations of mental health legislation in Victoria, Australia. University of Melbourne. Available at: https:\/\/minerva-access.unimelb.edu.au\/handle\/11343\/208997 (accessed 29 September 2023)."},{"key":"bibr26-00048674241240597","doi-asserted-by":"publisher","DOI":"10.1126\/science.adg1324"},{"key":"bibr27-00048674241240597","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01530-3"},{"key":"bibr28-00048674241240597","doi-asserted-by":"publisher","DOI":"10.1186\/s13011-022-00468-0"},{"key":"bibr29-00048674241240597","unstructured":"Multidisciplinary Association for Psychedelic Studies (2021) MAPS code of ethics for psychedelic psychotherapy (version 4). Multidisciplinary Association for Psychedelic Studies. Available at: https:\/\/maps.org\/wp-content\/uploads\/2022\/06\/MAPS_Psychedelic_Assisted_Psychotherapy_Code_of_Ethics_V4_22_June_2022_Final.pdf (accessed 7 September 2023)."},{"key":"bibr30-00048674241240597","doi-asserted-by":"publisher","DOI":"10.3390\/ph16010068"},{"key":"bibr31-00048674241240597","unstructured":"Office of Drug Control, Department of Health and Aged Care, Commonwealth (2023) Regulation of MDMA and psilocybine. Office of Drug Control, Department of Health and Aged Care, Commonwealth Government of Australia. Available at: www.odc.gov.au\/narcotic-and-psychotropic-drugs\/regulation-mdma-and-psilocybine (accessed 7 September 2023)."},{"key":"bibr32-00048674241240597","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2023.1554"},{"key":"bibr33-00048674241240597","doi-asserted-by":"publisher","DOI":"10.1080\/21507740.2022.2148771"},{"key":"bibr34-00048674241240597","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2021.103429"},{"key":"bibr35-00048674241240597","unstructured":"Retreat Guru (n.d.) Retreat Guru: Meditation & ayahuasca retreats, yoga holidays. Available at: http:\/\/retreat.guru\/search?subtopic=psilocybin&is_online&is_affordable&is_weekend&is_deluxe&top_rated (accessed 22 January 2024)."},{"key":"bibr36-00048674241240597","doi-asserted-by":"publisher","DOI":"10.1080\/21507740.2023.2188297"},{"key":"bibr37-00048674241240597","unstructured":"Royal Australian and New Zealand College of Psychiatrists (2023) Clinical memorandum: Therapeutic use of MDMA for PTSD and psilocybin for treatment resistant depression. Royal Australian and New Zealand College of Psychiatrists. Available at: www.ranzcp.org\/clinical-guidelines-publications\/clinical-guidelines-publications-library\/therapeutic-use-of-mdma-for-ptsd-and-psilocybin-for-treatment-resistant-depression (accessed 7 September 2023)."},{"key":"bibr38-00048674241240597","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2017.12.040"},{"key":"bibr39-00048674241240597","doi-asserted-by":"publisher","DOI":"10.1177\/02698811211069100"},{"key":"bibr40-00048674241240597","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02378-5"},{"key":"bibr41-00048674241240597","unstructured":"Skerritt J, Langham R (2023) Change to classification of MDMA and psilocybin to enable prescribing by authorised psychiatrists. Webinar. Available at: www.tga.gov.au\/presentations\/webinar-presentation-change-classification-mdma-and-psilocybin-enable-prescribing-authorised-psychiatrists (accessed 7 September 2023)."},{"key":"bibr42-00048674241240597","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1995"},{"key":"bibr43-00048674241240597","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.12481"},{"key":"bibr44-00048674241240597","doi-asserted-by":"publisher","DOI":"10.1136\/medethics-2020-106070"},{"key":"bibr45-00048674241240597","unstructured":"Therapeutic Goods Administration, Commonwealth Government of Australia (2023a) Access to MDMA (3,4-methylenedioxy-methamphetamine) and psilocybin for therapeutic purposes \u2013 information for psychiatrist prescribers (version 3.0). Therapeutic Goods Administration, Commonwealth Government of Australia. Available at: www.tga.gov.au\/products\/unapproved-therapeutic-goods\/mdma-and-psilocybin (accessed 7 September 2023)."},{"key":"bibr46-00048674241240597","unstructured":"Therapeutic Goods Administration, Commonwealth Government of Australia (2023b) Checklist for prescribing psychiatrists of MDMA or psilocybin. Therapeutic Goods Administration, Commonwealth Government of Australia. Available at: www.tga.gov.au\/resources\/resource\/checklists\/checklist-prescribing-psychiatrists-mdma-and-psilocybin (accessed 25 September 2023)."},{"key":"bibr47-00048674241240597","unstructured":"Therapeutic Goods Administration, Commonwealth Government of Australia (2023c) Notice of final decisions to amend (or not amend) the current Poisons Standard in relation to psilocybine and MDMA. Therapeutic Goods Administration, Commonwealth Government of Australia. Available at: www.tga.gov.au\/resources\/publication\/scheduling-decisions-final\/notice-final-decision-amend-or-not-amend-current-poisons-standard-june-2022-acms-38-psilocybine-and-mdma (accessed 7 September 2023)."},{"key":"bibr48-00048674241240597","unstructured":"Therapeutic Goods Administration, Commonwealth Government of Australia (n.d.) Medicinal cannabis: News and updates. Available at: www.tga.gov.au\/products\/unapproved-therapeutic-goods\/medicinal-cannabis-hub\/medicinal-cannabis-news-and-updates (accessed 4 February 2024)."},{"key":"bibr49-00048674241240597","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2022.2047929"},{"key":"bibr50-00048674241240597","first-page":"34","volume":"168","author":"Watson N","year":"2022","journal-title":"Precedent"}],"container-title":["Australian &amp; New Zealand Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/00048674241240597","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/00048674241240597","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/00048674241240597","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/00048674241240597","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:57:37Z","timestamp":1777373857000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/00048674241240597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,16]]},"references-count":50,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.1177\/00048674241240597"],"URL":"https:\/\/doi.org\/10.1177\/00048674241240597","relation":{},"ISSN":["0004-8674","1440-1614"],"issn-type":[{"value":"0004-8674","type":"print"},{"value":"1440-1614","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,16]]}}}